GMAB
Genmab AS
NASDAQ: GMAB · HEALTHCARE · BIOTECHNOLOGY
$57.29
+28.25% today
Updated 2026-10-28
Market cap
$27.47B
P/E ratio
35.17
P/S ratio
6.65x
EPS (TTM)
$1.27
Dividend yield
—
52W range
$24 – $60
Volume
4.1M
Genmab AS (GMAB) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$57.29
12-Month target
$25.57
2030 Target
—
Intrinsic (DCF)
$58.04
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.4B | $14.5B | $16.5B | $21.5B | $3.7B | $3.0B | $2.5B | $2.0B | $1.7B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: -18.11% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 19.10%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.